comprehensive -WSS

comprehensive

author：explore 2025-09-27 16:49:09 - browse：9

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： 'Vaccine

focus

WSS

Readout LOUD podcast: What to know about H5N1 bird flu

After gene therapy, two congenitally deaf children hear for the first time

Use wet bulb globe temperature, not heat index, to protect workers

Study fuels hope CAR

Telehealth startups turn to complex chronic diseases

First recipient of genetically engineered pig kidney has died

focus

comprehensive

focus

Medical records are filled with copy

5 ways to address the shortage of health care workers

Virginia high school admissions case could be legal follow

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Medical leaders decry Supreme Court decision on affirmative action

CDC wastewater surveillance dashboard to track bird flu hotspots

BioMarin wins approval for gene therapy to treat hemophilia A

Sanofi strikes deal with Novavax, boosting the vaccine maker

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare isn't yet testing food as medicine

focus

Ohio train derailment: Experts on toxic chemical risks

First recipient of genetically engineered pig kidney has died

Study: People of West African ancestry at greater risk of cardiac amyloidosis

STAT Madness 2024: Meet the contenders

Laying a path for careers in science

H5N1 communication has been strictly for the birds

hotspot

focus

knowledge

focus